TABLE 3b.
Known | Unknown | Total | |||||
---|---|---|---|---|---|---|---|
Codes | N | % | Codes | N | % | N | |
SSF 1: Carcinoembryonic Antigen (CEA) | 010, 020, 030 | 5214 | 53.9 | 997, 998, 999 | 4464 | 46.1 | 9678 |
SSF 2: Clinical Assessment of Regional Lymph Nodes | 000-120 | 7626 | 78.8 | 200, 400, 999 | 2052 | 21.2 | 9678 |
2a. Select Reg LN eval = 0, 1, 5, 9 | 000-120 | 3549 | 72.9 | 200, 400, 999 | 1317 | 28.1 | 4866 |
2b. Select Reg LN eval = 0, 1, 5, 9, and CS LN = 100-300, 800 | 010-120 | 654 | 58.2 | 000, 200, 400, 999 | 469 | 41.8 | 1123 |
SSF 3: Carcinoembryonic Antigen (CEA) Lab Value | 000-980 | 5194 | 53.7 | 997, 998, 999 | 4484 | 46.3 | 9678 |
SSF 4: Tumor Deposits | 000-081 | 6281 | 64.9 | 990, 998, 999 | 3397 | 35.1 | 9678 |
4a. Selected surgery codes 30-80 | 000-081 | 5081 | 82.8 | 990, 998, 999 | 1053 | 17.2 | 6134 |
SSF 6: Circumferential Resection Margin (CRM) | 000-981, 990-996 | 4972 | 51.4 | 998, 999 | 4706 | 48.6 | 9678 |
6a. Selected surgery codes 30-80 | 000-981, 990-996 | 4525 | 73.8 | 998, 999 | 1609 | 26.2 | 6134 |
SSF 8: Perineural Invasion | 000-010 | 6263 | 64.7 | 998, 999 | 3415 | 35.3 | 9678 |
8a.Selected surgery codes 30-80 | 000-010 | 5043 | 82.2 | 998, 999 | 1091 | 17.8 | 6134 |
SSF 9:KRAS | 010-020 | 716 | 7.4 | 997, 998, 999 | 8962 | 92.6 | 9678 |
9a. KRAS stage IV only | 010-020 | 362 | 21.3 | 997, 998, 999 | 1340 | 78.7 | 1702 |
Source: National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program: SEER 18 geographic areas: States of Connecticut, New Mexico, Utah, California (4 areas: San-Francisco, San Jose-Monterey, Los Angeles, Greater California), Hawaii, Iowa, New Jersey, Louisiana, Kentucky, Georgia (3 areas: Atlanta, Rural Georgia, and remainder of the state), Alaska Native Registry, and metropolitan areas of Detroit, Michigan and Seattle (Western Washington), Washington.
LN: Lymph nodes; Reg: Regional; eval: evaluation; CS: Collaborative Stage
Note: there were no cases for not applicable (codes 988 or blank).